Ozanimod for the treatment of relapsing remitting multiple sclerosis

@article{Rasche2018OzanimodFT,
  title={Ozanimod for the treatment of relapsing remitting multiple sclerosis},
  author={Ludwig Rasche and Friedemann Paul},
  journal={Expert Opinion on Pharmacotherapy},
  year={2018},
  volume={19},
  pages={2073 - 2086}
}
ABSTRACT Introduction: Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator under development by Celgene, for the treatment of relapsing remitting multiple sclerosis. Extensive clinical experience has become available for the related compound fingolimod, favoring the sphingosine 1-phosphate therapeutic concept. Off-target effects have been attributed to its low receptor specificity and have prompted the development of next generation sphingosine 1-phosphate receptor… 
An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis
TLDR
The itinerary leading to the approval of ozanimod for MS treatment and its peculiarities and potentiality inside the S1PR modulator family are retraces.
Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
TLDR
Ozanimod is a novel S1P (sphingosine-1-phosphate) receptor modulator used for the treatment of clinically isolated syndrome, relapsing–remitting, and secondary progressive forms of multiple sclerosis and has been proved to be both effective and well tolerated.
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
TLDR
Ozanimod appears to have a favorable benefit-risk profile versus fingolimod, which is associated with a lower risk of extended first-dose monitoring, conduction abnormalities including atrioventricular block and abnormal liver enzymes.
Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
TLDR
Findings suggested that ozanimod was associated with greater reductions of relapses, a lowered risk of disability progression at 3 months, and improved safety outcomes compared with DMF, and MAICs were conducted while adjusting for important treatment-effect modifiers and/or prognostic factors.
Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis
TLDR
A network meta-analysis (NMA) systematically evaluated the efficacy and acceptability of S1P receptors, as disease-modifying drugs, in the treatment of patients with MS, and indicated that Amiselimod (0.4 mg) is the most effective treatment strategy as a S 1P receptor for MS patients.
Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
TLDR
Adverse events are initially observed in phase 2 and 3 clinical trials, and further long-term data are collected in phase 3 extension studies, case series, and post-marketing reports, which highlight the need to periodically re-evaluate and adjust monitoring strategies to optimize treatment safety in an individualized approach.
Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression.
TLDR
The use of different therapeutic approaches to re-induce self-tolerance in autoreactive cells contributing to MS pathogenesis is presented and a Combination therapy using these tools may help to deal with the clinical disabilities and symptoms of the disease in the future.
Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ‐ a unique therapeutic target in inflammatory bowel disease
  • Jie Wang, I. Goren, +5 authors F. Rieder
  • Medicine
    Alimentary pharmacology & therapeutics
  • 2021
Ozanimod, a high selective sphingosine 1 phosphate (S1P) receptor (S1PR) 1/5 modulator was approved by the Food and Drug Administration for the treatment of adult patients with moderately to severely
...
1
2
...

References

SHOWING 1-10 OF 211 REFERENCES
Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
TLDR
The topline results of two phase-III randomized clinical trials demonstrate superiority of ocrelizumab over interferon beta in RRMS patients with regards to clinical and paraclinical outcome parameters.
An update on cladribine for relapsing-remitting multiple sclerosis
TLDR
Cladribine is well tolerated, it is dosed orally in cycles of one year, the need for regular blood testing during treatment is likely limited, and the two-year efficacy data for treatment of relapsing MS are at least in the same range as the most efficient licensed treatments.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
TLDR
This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
TLDR
Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.
Both cladribine and alemtuzumab may effect MS via B-cell depletion
TLDR
Cladribine induced only modest depletion of T cells, which may not be consistent with a marked influence on MS, based on previous CD4+ T-cell depletion studies, and the success seen with monoclonal CD20+ depletion, suggests that B-cell suppression could be the major direct mechanism of action.
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
TLDR
Findings suggest that S1PR modulation by fingolimod in both the immune system and CNS, producing a combination of beneficial anti‐inflammatory and possibly neuroprotective/reparative effects, may contribute to its efficacy in MS.
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
TLDR
The degree of lymphopenia in peripheral blood was not associated to the positive treatment response of fingolimod in RRMS patients, and there were no differences between groups in ARR, time to first relapse or time to six-month confirmed disability progression.
Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
  • R. Milo
  • Medicine
    Expert opinion on pharmacotherapy
  • 2015
TLDR
The mode of action and main characteristics of current immunomodulatory drugs for MS and their place in the therapeutic algorithm of the disease based on evidence from clinical trials are described, paving the road for personalized medicine in MS.
...
1
2
3
4
5
...